云顶新耀(01952)早盘涨幅扶持扩大,股价上涨5.86%,现报67.80港元,成交额2.92亿港元。
交银国际发布研报指出,云顶新耀近期举办研发日活动,集中展示其完全整合且本地化的AI+mRNA平台,及基于该平台的多款mRNA肿瘤药物研发进展,其中包含个性化肿瘤治疗性疫苗EVM16、通用型现货肿瘤治疗性疫苗EVM14以及自体生成CAR-T项目。
交银国际发布研报称,将云顶新耀(01952)的EVER001加入长期财务预测中,预计其经PoS调整后的销售峰值将超过15亿元人民币,上调其目标价至72.5港元,对应237亿港元目标估值和1.8倍收入达峰时的市销率,维持买入评级。
责任编辑:卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.